Focused Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Focused Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-160	Closed	-$14.3K	–	985
2023 Q4	$14.3K	Sell	160 -288	-64%	-$21.4K	﹤0.01%	488
2023 Q3	$32.7K	Sell	448 -18	-4%	-$1.44K	0.01%	351
2023 Q2	$38.8K	Sell	466 -21	-4%	-$1.76K	0.01%	344
2023 Q1	$37.1K	Sell	487 -41,779	-99%	-$3.47M	0.01%	352
2022 Q4	$3.51M	Buy	42,266 +549	+1%	+$44.4K	0.71%	26
2022 Q3	$3.31M	Buy	41,717 +595	+1%	+$50.2K	0.69%	26
2022 Q2	$3.05M	Sell	41,122 -75	-0.2%	-$5.63K	0.56%	35
2022 Q1	$3.7M	Buy	41,197 +3,870	+10%	+$357K	0.59%	28
2021 Q4	$4.18M	Buy	37,327 +1,162	+3%	+$140K	0.65%	25
2021 Q3	$4.55M	Buy	36,165 +1,087	+3%	+$140K	0.74%	22
2021 Q2	$4.75M	Buy	35,078 +2,676	+8%	+$352K	0.78%	22
2021 Q1	$4.39M	Sell	32,402 -3,969	-11%	-$594K	0.78%	20
2020 Q4	$5.12M	Buy	36,371 +261	+0.7%	+$33.4K	1%	16
2020 Q3	$4.02M	Buy	36,110 +549	+2%	+$61.5K	0.87%	17
2020 Q2	$3.98M	Buy	35,561 +1,383	+4%	+$136K	0.92%	17
2020 Q1	$2.65M	Buy	34,178 +34,114	+53,303%	+$3.02M	0.76%	19
2019 Q4	$6K	Buy	+64	New	+$5.54K	﹤0.01%	563

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Focused Wealth Management's XBI Position: Q1 2024 in Review

Focused Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2024, closing a stake of 160 shares — an estimated $14.3K sold.

Focused Wealth Management first reported a position in XBI in Q4 2019 and held it in 17 quarters. The position peaked at $5.12M in Q4 2020. 781 funds tracked by Wall St. Rank hold XBI as of Q1 2024.

Focused Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2024 after selling out during the quarter.
Focused Wealth Management sold 160 State Street SPDR S&P Biotech ETF shares in Q1 2024, an estimated $14.3K.
Focused Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and held it in 17 quarters.
Focused Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $5.12M in Q4 2020.
781 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.